Products
HER2/ErbB2 antibody
- Product Name
- HER2/ErbB2 antibody
- Catalogue No.
- FNab03833
- Size
- 100μg
- Form
- liquid
- Purification
- Immunogen affinity purified
- Purity
- ≥95% as determined by SDS-PAGE
- Clonality
- polyclonal
- Isotype
- IgG
- Storage
- PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Immunogen
- Immunogen
- v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog(avian)
- Alternative Names
- CD340 antibody, ERBB2 antibody, HER 2 antibody, HER 2/neu antibody, HER2 antibody, MLN 19 antibody, MLN19 antibody, NEU antibody, NGL antibody, p185 antibody, p185erbB2 antibody, Proto oncogene c ErbB 2 antibody, Proto oncogene Neu antibody, TKR1 antibody
- UniProt ID
- P04626
- Observed MW
- 185 kDa
Application
- Tested Applications
- ELISA, WB, IHC, FC, IP
- Recommended dilution
- WB: 1:1000-1:10000; IP: 1:200-1:2000; IHC: 1:50-1:200
Validated Images
HeLa cells were subjected to SDS PAGE followed by western blot with FNab03833(ERBB2 antibody) at dilution of 1:300
IP Result of anti-HER2/ErbB2 (IP:FNab03833, 5ug; Detection:FNab03833 1:500) with SGC-7901 cells lysate 2400ug.
Immunohistochemistry of paraffin-embedded human breast cancer using FNab03833(ERBB2 antibody) at dilution of 1:50
- Background
- HER2, also known as ErbB2 and Neu, is a 185-kDa transmembrane glycoprotein that is a member of the epidermal growth factor(EGF) receptor family of receptor tyrosine kinases. It has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas. This antibody raised against a synthesized peptide corresponding to 1237-1255aa of human HER2 recognizes the 185-kDa full-length glycosylated form and other lower molecular-mass forms of HER2, including the truncated form.
